Therapeutic eradication choices in Helicobacter pylori infection in children

Marco Manfredi1, Giancarlo Gargano2, Pierpacifico Gismondi3

  • 1Chief of Pediatric Unit, Maternal and Child Department, Azienda USL-IRCCS di Reggio Emilia, Sant'Anna Hospital, Castelnovo ne' Monti, Via Roma, 2, Reggio Emilia 42035, Italy.

Insights

Pediatric Helicobacter pylori (H. pylori) treatment differs from adults. Gastroscopy with susceptibility testing is recommended before eradication to identify causes and improve success rates in children.

Area of Science:

  • Pediatric Gastroenterology
  • Infectious Diseases
  • Microbiology

Background:

  • H. pylori eradication recommendations differ between pediatric and adult populations.
  • Adult H. pylori treatment is standard due to associated disease risks.
  • Pediatric guidelines advise against a simple 'test and treat' approach for H. pylori in children.

Purpose of the Study:

  • To review current H. pylori eradication strategies in children.
  • To emphasize the importance of diagnostic procedures before treatment in pediatric cases.
  • To explore alternative and less common therapeutic options for H. pylori in children.

Main Methods:

  • Review of pediatric international guidelines for H. pylori eradication.
  • Analysis of diagnostic approaches including gastroscopy and antimicrobial susceptibility testing.
  • Evaluation of antibiotic regimens, including triple and quadruple therapies, and their suitability for children.

Main Results:

  • Gastroscopy with susceptibility testing is crucial for evaluating symptoms and guiding H. pylori eradication in children.
  • Limited antibiotic availability in pediatrics necessitates susceptibility-guided treatment to minimize failure.
  • Standard triple and quadruple therapies, while options, may have side effects and compliance issues in children.

Conclusions:

  • H. pylori treatment in children requires a comprehensive approach beyond just eradication.
  • Antimicrobial susceptibility testing is vital for effective pediatric H. pylori therapy.
  • Further research into alternative treatments is needed to improve efficacy and tolerability in pediatric patients.

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
472
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
121
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
527
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
478
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
164
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
345